Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents
Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents
复制标题
DOI：
10.1128/jcm.02116-07
复制
发表时间：
2008-03-01
影响因子：
9.4
通讯作者：
Johnson, Elizabeth M.
中科院分区：
文献类型：
--
作者：
Borman, Andrew M.;Petch, Rebecca;Johnson, Elizabeth M.
2005年，尼瓦里假丝酵母（Candida nivariensis）是一种与光滑假丝酵母（Candida glabrata）遗传相关的酵母菌，在西班牙一家医院的三名患者身上分离出该菌后被描述。在2005年和2006年之间，16个真菌菌株与C nivariensis的表型相似性提交给英国真菌学参考实验室进行鉴定。这些菌株来源于英国12家不同医院的患者的各种临床标本，包括深部，通常是无菌部位。PCR扩增和核核糖体基因盒的D1D2和内部转录间隔区1（ITS1）区域的测序证实，来自英国的这些分离物与C. nivariensis。生物化学，C。glabrata和C. nivariensis的区别在于它们同化海藻糖的不同能力。然而，与最初发表的研究结果相比，我们发现C。glabrata分离物，而C. nivariensis分离物能够同化这种底物。抗真菌药敏试验表明，C。nivariensis分离物比C. glabrata分离株对伊曲康唑、氟康唑和伏立康唑的MIC显著高于C.光滑菌株最后，对C.通过对ITS2区域的焦磷酸测序可以快速区分nivariensis和其他常见的致病真菌。根据这些数据，我们认为C. nivariensis应被视为临床上重要的新兴病原真菌。
In 2005, Candida nivariensis, a yeast species genetically related to Candida glabrata, was described following its isolation from three patients in a single Spanish hospital. Between 2005 and 2006, 16 fungal isolates with phenotypic similarities to C nivariensis were submitted to the United Kingdom Mycology Reference Laboratory for identification. The strains originated from various clinical specimens, including deep, usually sterile sites, from patients at 12 different hospitals in the United Kingdom. PCR amplification and sequencing of the D1D2 and internal transcribed spacer 1 (ITS1) regions of the nuclear ribosomal gene cassette confirmed that these isolates from the United Kingdom are genetically identical to C. nivariensis. Biochemically, C. glabrata and C. nivariensis are distinguished by their differential abilities to assimilate trehalose. However, in contrast to the original published findings, we found that C. glabrata isolates, but not C. nivariensis isolates, are capable of assimilating this substrate. Antifungal susceptibility tests revealed that C. nivariensis isolates are less susceptible than C. glabrata isolates to itraconazole, fluconazole, and voriconazole and to have significantly higher flucytosine MICs than C. glabrata strains. Finally, C. nivariensis could be rapidly distinguished from the other common pathogenic fungus species by pyrosequencing of the ITS2 region. In the light of these data, we believe that C. nivariensis should be regarded as a clinically important emerging pathogenic fungus.